Novo Nordisk

The agreement includes Cardior’s lead compound CDR132L, currently in phase 2 clinical development for the treatment of heart…

According to the KOLs interviewed by GlobalData, the diagnostic and management tools for obesity need to be updated and patients…

The investment will significantly increase the capacity of the manufacturing site, adding aseptic production and finished…

The constrained supply of Wegovy and the necessity of ongoing obesity management support are key considerations

The acquisition of Inversago includes the company’s lead development asset INV-202, an oral CB1 inverse agonist

Vikrant Shrotriya, CVP & MD, Novo Nordisk India in an interaction with Express Pharma growth opportunities in pharma sector…

This week-long summer camp will host 100 exceptional students coming together from across the world  

Orchestrate a 90-minute ride from Bandra to Worli in Mumbai to highlight how obesity is becoming a public health concern all over…

Vikrant Shrotriya, MD and CVP, Novo Nordisk India, talks to Express Pharma about the potential and opportunities that the Indian…

The company is in a drawn-out production revamp after a contractor filling Wegovy injection pens ran into problems late last year